Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum GKM3
- Development stage
- Preclinical
- Lead developer
- Grape King Bio
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum GKM3 is a specific probiotic strain of the species Lactobacillus plantarum (now also classified as Lactiplantibacillus plantarum). It is used as a dietary supplement and functional food ingredient, primarily for its potential health benefits related to gut health, weight management, anti-aging effects, and cognitive function. Preclinical studies in animal models have shown that supplementation with L. plantarum GKM3 can delay aging processes, alleviate age-related cognitive impairment, reduce oxidative stress in the brain, lower amyloid-β accumulation (a marker associated with neurodegeneration), and improve behavioral outcomes[1][5]. In humans, it has been marketed for supporting weight loss by reducing body fat and appetite while improving bowel movements and immune function[4]. The mechanism of action involves modulation of the gut microbiota and reduction of oxidative stress markers; it may also influence metabolic parameters such as triglyceride levels[1][4].
- Brand names
- GKB Lactobacillus Plantarum GKM3
- Other names
- L. plantarum GKM3Lactiplantibacillus plantarum GKM3
Beyond the preview
Go deeper on lactobacillus plantarum GKM3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum GKM3.